Earnings

Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients

Oct 23, 2026 · 06:36 AM ET· updated 1h ago

Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today announced

Why It Matters

Tango Therapeutics tested a two drug cancer treatment on 22 patients. Early results looked encouraging, but the study is still very small and ongoing.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

TNGX25.41

-2.52 (-9.02%)

RVMD189.16

-5.12 (-2.64%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.